Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent.
Topical application of the drugs at the pathological sites offers potential advantages of delivering the drug directly to the site of action. The main aim of this work was to formulate and evaluate Miconazole nitrate (MN) loaded solid lipid nanoparticles (SLN) for topical application. MN-loaded SLN were prepared by modified solvent injection method and characterized for shape, surface morphology, particle size, and drug entrapment. These solid lipid nanoparticles were spherical in shape with smooth surface and possessed mean average size of 206.39 +/- 9.37 nm. In vitro drug release of MN-loaded SLN-bearing hydrogel was compared with MN suspension and MN hydrogel; MN-loaded SLN-bearing hydrogel depicted a sustained drug release over a 24-h period. Tape stripping experiments demonstrated 10-fold greater retention with MN-loaded SLN-bearing hydrogel as compared to MN suspension and MN hydrogel. The in vivo studies were performed by infecting the rats with candida species. It was observed that MN-loaded SLN-bearing hydrogel was more efficient in the treatment of candidiasis. Results indicate that MN-loaded SLN-bearing hydrogel provides a sustaining MN topical effect as well as quicker relief from fungal infection.
Jain
Safal
S
Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar (M. P.) 470003, India.
Jain
Sanjay
S
Khare
Piush
P
Gulbake
Arvind
A
Bansal
Divya
D
Jain
Sanjay K
SK
D000179:Acrylates / Q000009:adverse effects / Q000737:chemistry; D000279:Administration, Cutaneous; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000032:analysis / Q000493:pharmacokinetics / Q000627:therapeutic use; D002176:Candida albicans / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy; D055598:Chemical Phenomena; D003881:Dermatomycoses / Q000188:drug therapy; D004339:Drug Compounding; D016503:Drug Delivery Systems; D020100:Hydrogels; D054709:Lecithins / Q000009:adverse effects / Q000737:chemistry*; D008297:Male; D008825:Miconazole / Q000008:administration & dosage* / Q000032:analysis / Q000493:pharmacokinetics / Q000627:therapeutic use; D053758:Nanoparticles / Q000009:adverse effects / Q000737:chemistry* / Q000648:ultrastructure; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000187:drug effects / Q000378:metabolism; D023422:Skin Irritancy Tests; D014280:Triglycerides / Q000009:adverse effects / Q000737:chemistry*
D000179:Acrylates; D000935:Antifungal Agents; D020100:Hydrogels; D054709:Lecithins; D014280:Triglycerides; D008825:Miconazole; C453622:carbopol 934P; C022618:tristearin